Online citations, reference lists, and bibliographies.
← Back to Search

Critical Perspectives On International Pharmaceutical Innovation

C. W. Callaghan
Published 2019 · Economics

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper aims to argue that certain insights offered by Kuhn and Foucault may be of use to those seeking to resist a global paradigm of inequality in access to the outcomes of pharmaceutical development. It is further argued that these relationships are not independent of certain power relationships. This critical review seeks to highlight certain of these power relationships, and to suggest how they might be better managed to ensure more equitable outcomes for those in society that are most vulnerable to innovation failure.,This research takes the form of a critical review paper, seeking to develop theory though a synthesis of literature.,Unlike market incentives, it might be the research process itself that is most vulnerable to stakeholder resistance to slow and unequal delivery of life-saving pharmaceutical development. Given that a lack of responsiveness to societal needs can itself be considered unethical, Kuhnian theory predicting pharmaceutical innovation failure is related to what Foucault describes as a system of oppression, whereby power relationships disadvantage those most vulnerable and powerless.,Given the rise of movements like citizen science and participant-led research, as well as new ethical frameworks premised on increasing accountability in science, Foucault’s principles are considered to echo a general trend towards the democratisation of science, and towards increasing the responsiveness of pharmaceutical development to societal needs.,A novel synthesis of literature is undertaken, offering useful theoretical insights into how social actors might contribute to enabling a more responsive system of international healthcare business.
This paper references
10.4018/IJSKD.2017040104
The Probabilistic Innovation Field of Scientific Enquiry
C. Callaghan (2017)
10.1080/20421338.2017.1341093
Scientific real-time research problem-solving and pharmaceutical innovation
C. Callaghan (2017)
10.1080/15265161.2015.1054162
Ethics Preparedness for Public Health Emergencies: Recommendations From the Presidential Bioethics Commission
Elizabeth Fenton (2015)
10.1093/bmb/ldv035
Crowdsourced 'R&D' and medical research.
C. W. Callaghan (2015)
10.1155/2014/260567
Recent Advances towards Validating Efficacy and Safety of African Traditional Medicines
John R S Tabuti (2014)
10.3390/jpm2030093
Health 2050: The Realization of Personalized Medicine through Crowdsourcing, the Quantified Self, and the Participatory Biocitizen
M. Swan (2012)
10.1038/nm0307-304
Aligning pharmaceutical innovation with medical need
C. Nathan (2007)
10.1016/j.jhealeco.2008.01.002
Market incentives and pharmaceutical innovation.
Wesley Yin (2008)
10.1093/JHUMAN/HUN006
South Africa's Treatment Action Campaign: Combining Law and Social Mobilization to Realize the Right to Health
M. Heywood (2009)
10.1016/0966-842X(96)30028-0
Antibiotic resistance: the new apocalypse?
C. Ash (1996)
10.1177/0963662513518154
Why should we promote public engagement with science?
J. Stilgoe (2014)
10.1257/JEP.31.3.175
Federal Budget Policy with an Aging Population and Persistently Low Interest Rates
D. Elmendorf (2017)
10.25159/1998-8125/6041
A new paradigm of knowledge management: Crowdsourcing as emergent research and development
C. Callaghan (2019)
10.1038/507294a
Technology: The $1,000 genome
E. Hayden (2014)
10.1002/ETC.5620131203
Uncertainty, complexity and post-normal science
S. Funtowicz (1994)
10.1038/nbt.2692
The ethics of participant-led biomedical research
E. Vayena (2013)
10.1056/NEJMoa0908481
Critical care services and 2009 H1N1 influenza in Australia and New Zealand.
S. Webb (2009)
10.1016/J.FUTURES.2010.08.017
The study of futures, and the analysis of power
B. Hamm (2010)
10.1089/big.2012.0002
The Quantified Self: Fundamental Disruption in Big Data Science and Biological Discovery
Melanie Swan (2013)
10.1525/bio.2009.59.11.9
Citizen Science: A Developing Tool for Expanding Science Knowledge and Scientific Literacy
R. Bonney (2009)
10.1016/J.MIB.2003.08.003
Why is big Pharma getting out of antibacterial drug discovery?
S. Projan (2003)
10.1038/nrd3681
Diagnosing the decline in pharmaceutical R&D efficiency
J. Scannell (2012)
10.1136/QSHC.2004.010918
Ignaz Semmelweis and the birth of infection control
M. Best (2004)
10.1068/a45649
Why Solar Radiation Management Geoengineering and Democracy Won't Mix
B. Szerszynski (2013)
10.1108/CPOIB-06-2013-0021
A critical perspective on corporate social responsibility
S. Banerjee (2014)
10.1023/A:1025384819575
Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents
P. Danzon (2004)
10.1111/J.1536-7150.2011.00820.X
Pharmaceutical high profits: the value of R&D, or oligopolistic rents?
J. Spitz (2012)
10.1001/jama.2016.12335
Preparing for Better Health and Health Care for an Aging Population.
J. Rowe (2016)
10.5751/ES-04705-170229
Public Participation in Scientific Research: a Framework for Deliberate Design
Jennifer Shirk (2012)
10.3201/EID0402.980204
Legal issues associated with antimicrobial drug resistance.
D. Fidler (1998)
10.1002/phar.1868
Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications
Katherine H. Luepke (2017)
10.1128/JVI.01244-13
Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group
R. D. de Groot (2013)
10.1016/j.ijdrr.2016.05.004
Disaster management, crowdsourced R&D and probabilistic innovation theory: Toward real time disaster response capability
C. W. Callaghan (2016)
10.1086/448181
The Subject and Power
Michel Foucault (1982)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar